Technetium (99mTc) fanolesomab

From Wikipedia, the free encyclopedia

Technetium (99mTc) fanolesomab?
Therapeutic monoclonal antibody
Source	Mouse
Target	CD15
Identifiers
CAS number	?
ATC code	?
PubChem	?
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Intravenous

Technetium (^99mTc) fanolesomab (trade name NeutroSpec, manufactured by Palatin Technologies) is a mouse monoclonal antibody formerly used to aid in the diagnosis of appendicitis. It is labeled with a radioisotope, technetium-99m (^99mTc).

Contents 1 History and use 2 Deaths and associated recall 3 References 4 External links

[edit] History and use

NeutroSpec was approved by the U.S. Food and Drug Administration (FDA) in June 2004 for imaging of patients with symptoms of appendicitis. It consisted of a monoclonal antibody against CD15, labeled with technetium-99 so as to be visible on a gamma camera. Since anti-CD15 antibodies bind selectively to neutrophils, it could be used to localize the site of an infection.

[edit] Deaths and associated recall

The FDA received reports from Palatin of 2 deaths and 15 life-threatening adverse events in patients who had received NeutroSpec.

These events occurred within minutes of administration of NeutroSpec and included shortness of breath, low blood pressure, and cardiopulmonary arrest. Affected patients required resuscitation with intravenous fluids, blood pressure support, and oxygen. Most, but not all, of the patients who experienced these events had existing cardiac and/or pulmonary conditions that may have placed them at higher risk for these adverse events. A review of all post-marketing reports showed an additional 46 patients who experienced adverse events that were similar but less severe. All of the reactions occurred immediately after NeutroSpec was administered.^[1]

Marketing of the product was suspended in December 2005.

[edit] References

[edit] External links

• Technetium (^99mTc) Fanolesomab from Micromedex

v • d • e Mouse monoclonal antibodies ("-o-") "govo" (ovarian tumor) Abagovomab, Igovomab, Oregovomab "limo" (immune system) Afelimomab, Dorlimomab aritox, Elsilimomab, Faralimomab, Gavilimomab, Inolimomab, Maslimomab, Nerelimomab, Odulimomab, Telimomab aritox, Vepalimomab, Zolimomab aritox "tumo" (miscellaneous tumor) Altumomab, Anatumomab mafenatox, Arcitumomab, Bectumomab, Detumomab, Epitumomab, Epitumomab cituxetan, Ibritumomab tiuxetan, Minretumomab, Mitumomab, Naptumomab estafenatox, Nofetumomab merpentan, Pemtumomab, Pintumomab, Satumomab, Taplitumomab paptox, Tositumomab "leso" (infectious lesions) Besilesomab, Fanolesomab, Lemalesomab, Sulesomab "ciro" (cardiovascular) Biciromab brallobarbital, Imciromab "pro" (prostate tumor) Capromab "baco" (bacterial) Edobacomab "colo" (colonic tumor) Edrecolomab, Nacolomab tafenatox